NAS:IONS (USA) Also Trade In: Germany Mexico Switzerland UK

Ionis Pharmaceuticals Inc $ 61.41 -1.13 (-1.81%)

Volume:

618,254

Avg Vol (1m):

1,217,318

Market Cap $:

8.58 Bil

Enterprise Value $:

7.30 Bil

P/E (TTM):

127.90

P/B:

6.21

5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

View Full Chart

What is PE Ratio (TTM)?

Current and historical daily P/E ratio for Ionis Pharmaceuticals Inc () from 1991 to Jan 21 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Ionis Pharmaceuticals stock (IONS) PE ratio as of Jan 21 2021 is 127.9. More Details

Ionis Pharmaceuticals PE Ratio (TTM) Chart

EMBED

Ionis Pharmaceuticals PE Ratio (TTM) Historical Data

View and export this data going back to 1991. Start your Free Trial

Total 1254

Ionis Pharmaceuticals PE Ratio (TTM) Historical Data
Date	PE Ratio (TTM) Data	Date	PE Ratio (TTM) Data
2021-01-21	127.9	2020-11-19	105.1
2021-01-20	130.3	2020-11-18	105.6
2021-01-19	127.2	2020-11-17	109.4
2021-01-18	127.7	2020-11-16	108.7
2021-01-15	127.7	2020-11-13	107.4
2021-01-14	127.8	2020-11-12	102.6
2021-01-13	124.3	2020-11-11	102.5
2021-01-12	123.2	2020-11-10	104.5
2021-01-11	129.4	2020-11-09	104.4
2021-01-08	127.2	2020-11-06	101.3
2021-01-07	123.2	2020-11-05	101.5
2021-01-06	117.1	2020-11-04	99.2
2021-01-05	116.5	2020-11-03	97.9
2021-01-04	118.3	2020-11-02	97.4
2021-01-01	117.8	2020-10-30	97.8
2020-12-31	117.8	2020-10-29	97.6
2020-12-30	119.2	2020-10-28	95.5
2020-12-29	118.8	2020-10-27	97.9
2020-12-28	122.8	2020-10-26	97.9
2020-12-25	124.3	2020-10-23	98.6
2020-12-24	124.3	2020-10-22	98.3
2020-12-23	125.6	2020-10-21	96.6
2020-12-22	122.1	2020-10-20	98.8
2020-12-21	115.3	2020-10-19	98.3
2020-12-18	113.2	2020-10-16	98.2
2020-12-17	106.7	2020-10-15	100.6
2020-12-16	103.7	2020-10-14	99.4
2020-12-15	107.3	2020-10-13	99.9
2020-12-14	99.7	2020-10-12	96.8
2020-12-11	95.4	2020-10-09	95.7
2020-12-10	96.6	2020-10-08	97.6
2020-12-09	97.2	2020-10-07	96.7
2020-12-08	102.0	2020-10-06	94.4
2020-12-07	104.8	2020-10-05	99.1
2020-12-04	106.7	2020-10-02	95.1
2020-12-03	106.2	2020-10-01	99.5
2020-12-02	106.9	2020-09-30	98.9
2020-12-01	106.5	2020-09-29	101.0
2020-11-30	105.3	2020-09-28	102.2
2020-11-27	106.5	2020-09-25	55.3
2020-11-26	104.7	2020-09-24	55.3
2020-11-25	104.7	2020-09-23	56.1
2020-11-24	104.3	2020-09-22	57.7
2020-11-23	104.7	2020-09-21	57.1
2020-11-20	102.4	2020-09-18	58.4

Ionis Pharmaceuticals PE Ratio (TTM) Comparison

Company	Market Cap(Mil)	PE Ratio (TTM)

Business Description

Industry Healthcare » Biotechnology » NAICS : 325412 NAICS : 2834

Compare NAS:EXEL NAS:IMMU NAS:ACAD NAS:ASND NAS:ALLO NAS:JAZZ NAS:RETA NAS:XLRN NAS:ADPT NAS:IOVA OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY

Traded in other countries ISI.Germany IONS.Mexico IONS.Switzerland 0JDI.UK IONS.USA

Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Ionis' broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Product

Business

Information

About

Affiliate Program

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names

Earn affiliate commissions by embedding GuruFocus Charts

GuruFocus Affiliate Program: Earn up to $400 per referral. Detailed

Disclaimers

GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.